pharmaphorum1d
GSK says Nucala hits the target in new COPD trial
GSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called METREX and METREO. METREX involved patients with a range of ...
Hosted on MSN1mon
FDA to review GSK’s Nucala for COPD
Nucala is already approved in the US for four ... This assessment can provide insights into a COPD patient's likelihood of experiencing exacerbations and worsening of their condition and guide ...
pharmaphorum4d
EU clears GSK’s asthma drug Nucala in patient-friendly format
The European Commission has approved two new delivery formats for Nucala (mepolizumab) – a pre-filled pen injector and a pre-filled safety syringe – that will allow patients with eosinophilic ...
Hosted on MSN4mon
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
Data from the MATINEE study showed that in patients treated for up to 2 years, the addition of Nucala to inhaled maintenance therapy led to a statistically significant and clinically meaningful ...
Nasdaq1mon
GSK: FDA Accepts For Review Submission For New Indication Of Nucala In COPD
The submission seeks an indication for the use of Nucala as an add-on maintenance treatment for patients with COPD with an eosinophilic phenotype. The Prescription Drug User Fee Act (PDUFA ...
GlobalData on MSN19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Yahoo Finance19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
“We are delighted that Nucala has been approved in China as a treatment for CRSwNP, a chronic condition for which new and effective treatments are needed. “Patients now have a non-surgical ...